MLN4924: Unraveling Neddylation Beyond CRLs in Cancer Research

Introduction: Redefining the Landscape of Neddylation Pathway Inhibition

In the realm of cancer biology research, the neddylation pathway has emerged as a critical regulator of cellular homeostasis, protein turnover, and tumorigenesis. MLN4924, also known as Pevonedistat, is a potent and selective NEDD8-activating enzyme inhibitor (MLN4924), widely recognized for its ability to block cullin-RING ligase (CRL) ubiquitination. While previous studies and reviews—such as "MLN4924: Selective NAE Inhibitor Targeting Neddylation in..."—have focused extensively on MLN4924’s applications in solid tumor models and classical CRL substrates, this article delivers a new perspective: the expanding significance of neddylation in non-cullin targets, particularly the mTORC1 pathway, and how MLN4924 opens up innovative anti-cancer therapeutic strategies by modulating both canonical and non-canonical neddylation events.

Neddylation Pathway: A Complex Regulatory Network

Neddylation is a ubiquitin-like post-translational modification wherein the NEDD8 protein is covalently attached to lysine residues of target substrates. The enzymatic cascade involves: (1) the E1 NEDD8-activating enzyme (NAE), (2) E2 NEDD8-conjugating enzymes (notably UBE2M/UBC12 and UBE2F), and (3) various E3 NEDD8 ligases. The most studied function of neddylation is the activation of CRLs (cullin-RING ligases), which, in turn, regulate the ubiquitin-proteasome system and control the degradation of pivotal cellular proteins such as cyclins, p27, and CDT1. Dysregulation of neddylation is implicated in a broad spectrum of human cancers, offering a compelling rationale for therapeutic intervention.

Mechanism of Action of MLN4924: From CRLs to Non-Cullin Substrates

Biochemical Specificity and Selectivity

MLN4924 (B1036) exhibits high potency and selectivity as an NAE inhibitor, with an IC₅₀ of 4 nM. It competitively occupies the nucleotide-binding site of NAE, blocking the formation of the NEDD8-adenylate intermediate required for downstream neddylation. This results in a marked reduction in the formation of Ubc12–NEDD8 thioester and NEDD8–cullin conjugates, thereby impairing CRL-mediated ubiquitination and subsequent protein degradation. Importantly, MLN4924 demonstrates robust selectivity over other related activating enzymes such as UAE, SAE, UBA6, and ATG7, ensuring targeted intervention in the neddylation pathway without broad off-target effects.

Cellular and In Vivo Effects

In cellular models, such as HCT-116 colorectal carcinoma cells, MLN4924 induces dose-dependent inhibition of NAE activity, leading to the accumulation of CRL substrates like CDT1. The aberrant buildup of these substrates triggers cell cycle arrest and apoptotic pathways. In vivo, subcutaneous administration of MLN4924 at 30–60 mg/kg effectively suppresses tumor growth in various xenograft models—including HCT-116, H522 lung tumor, and Calu-6 lung carcinoma—while demonstrating favorable tolerability and minimal systemic toxicity.

Beyond Cullins: MLN4924 as a Gateway to Non-Canonical Neddylation Research

While most existing reviews—such as "MLN4924: Selective NAE Inhibitor Illuminates Neddylation ..."—emphasize MLN4924’s use in classic CRL research, recent breakthroughs have unveiled its broader impact on non-cullin proteins. A seminal study (Zhang et al., 2025) identified RHEB—a small GTPase and pivotal activator of the mTORC1 pathway—as a novel neddylation substrate. This finding redefines the functional landscape of neddylation and highlights new applications for MLN4924 in dissecting oncogenic signaling beyond traditional paradigms.

RHEB Neddylation and mTORC1: A New Axis in Tumorigenesis

RHEB neddylation, mediated by the UBE2F-SAG axis, enhances mTORC1 activity by promoting RHEB’s lysosomal localization and GTP-binding affinity. Liver-specific knockout of UBE2F or inhibition of neddylation attenuates mTORC1-driven tumorigenesis in hepatocellular carcinoma (HCC) models, underscoring the therapeutic promise of targeting the broader neddylation network. MLN4924, by abrogating NAE activity, is uniquely positioned to disrupt both cullin and non-cullin neddylation, providing a dual-pronged strategy to impair tumor growth and survival mechanisms.

Comparative Analysis: MLN4924 Versus Alternative Neddylation and Ubiquitination Inhibitors

While proteasome inhibitors such as bortezomib and ubiquitin-activating enzyme (UAE) inhibitors have demonstrated efficacy in select malignancies, their broad-spectrum activity often leads to systemic toxicity and compensatory resistance mechanisms. MLN4924’s exquisite selectivity for NAE offers a more refined approach, targeting the neddylation pathway at its apex and sparing related ubiquitin-like modifiers. Further, as illustrated in "MLN4924 and Neddylation: Unraveling E2 Enzyme Selectivity...", the unique ability of MLN4924 to dissect E2 enzyme specificity—particularly in the context of UBE2F and UBE2M—enables researchers to distinguish between cullin and non-cullin neddylation events, a feature not readily achievable with alternative inhibitors.

Advanced Applications: MLN4924 in Cancer Biology Research and Anti-Cancer Therapeutic Development

Dissecting the Ubiquitin-Proteasome System and Cell Cycle Regulation

MLN4924 has become an indispensable tool in cancer biology research, facilitating the study of the ubiquitin-proteasome system, cell cycle checkpoints, and apoptosis. Its impact extends from elucidating the mechanisms of CRL substrate accumulation to uncovering novel regulatory nodes in cell proliferation and DNA damage response. For instance, the stabilization of CDT1 upon MLN4924 treatment highlights neddylation’s role in maintaining genomic integrity and orderly cell cycle progression.

Modeling Tumor Growth Inhibition in Xenograft and Solid Tumor Models

In preclinical studies, MLN4924’s ability to inhibit tumor growth has been validated across diverse solid tumor models, including colorectal, lung, and liver cancers. Its favorable pharmacological profile—solid form, robust solubility in DMSO and ethanol, and high in vivo tolerability—enables versatile experimental designs in both in vitro and in vivo settings. The compound’s storage stability at -20°C further supports its adoption in high-throughput and longitudinal studies.

Expanding the Scope: Targeting mTORC1 Pathway and Metabolic Rewiring

Building on the foundational role of MLN4924 in CRL research, the discovery of RHEB neddylation provides a new frontier for investigating metabolic reprogramming in cancer. Since mTORC1 integrates environmental cues to orchestrate anabolic and catabolic processes—functions co-opted by rapidly proliferating tumor cells—targeting RHEB neddylation via NAE inhibition may attenuate tumor progression and overcome resistance to classical mTOR inhibitors. This paradigm shift distinguishes the present analysis from existing articles like "MLN4924: Redefining Cancer Research via Neddylation Pathw...", which primarily focus on CRL-related mechanisms. Here, we emphasize the therapeutic potential of MLN4924 in modulating the entire neddylation network, encompassing both cullin and non-cullin substrates.

Future Directions: MLN4924 as a Platform for Novel Anti-Cancer Strategies

The integration of MLN4924 into cancer research pipelines is catalyzing the development of next-generation anti-cancer therapeutics. By enabling precise inhibition of the neddylation pathway—including emerging non-cullin targets—MLN4924 paves the way for personalized interventions in solid tumors, hematological malignancies, and metabolic liver diseases. Further research is warranted to elucidate the interplay between neddylation, ubiquitination, and other post-translational modifications, as well as to optimize combinatorial regimens with mTORC1 inhibitors, immune checkpoint modulators, and metabolic therapies.

Conclusion and Future Outlook

MLN4924 stands at the vanguard of neddylation research, offering unparalleled specificity as a NEDD8-activating enzyme inhibitor. Its dual capacity to block CRL-mediated ubiquitination and disrupt non-cullin neddylation—such as the newly unveiled RHEB-mTORC1 axis—positions it as a transformative tool for cancer biology research and anti-cancer therapeutic development. As the landscape of neddylation biology expands, MLN4924 will continue to illuminate the molecular circuitry underlying tumorigenesis and empower the discovery of innovative treatments for solid tumors and beyond.

References
Zhang F, Xiong X, Li Z, et al. RHEB neddylation by the UBE2F-SAG axis enhances mTORC1 activity and aggravates liver tumorigenesis. The EMBO Journal. 2025;44(4):1185–1219. https://doi.org/10.1038/s44318-024-00353-5